The interstitial deletion del(14)(q24.1q32.33) is a recurrent chromosomal change in B-cell chronic lymphocytic leukemia (CLL) and other B-cell lymphomas. 1, 2 The break points of this deletion are located in the immunoglobulin heavy chain (IGH)-locus in 14q32.33 and in a region in 14q24.1 containing the ZFP36L1 gene ( 1 and our own unpublished observations). Activation of a candidate oncogene centromeric of the deletion break point in 14q24.1 through juxtaposition to the IGH locus, yet could not be unambiguously shown. 1 An alternative hypothesis is that the deletion might inactivate a tumor suppressor gene. Among many other genes, the TNF receptor-associated factor 3 (TRAF3)-gene in 14q32.32 is located within the deleted region. The TRAF3 protein negatively regulates the NF-kB pathway and has been shown to be recurrently affected by biallelic TRAF3 deletion and inactivating mutation in multiple myeloma and Waldenström's macroglobulinemia. [3] [4] [5] Furthermore, B-cellspecific TRAF3 À/À mice show remarkably prolonged B-cell survival and highly expanded B-cell compartments in secondary lymphoid organs. 6 These facts qualify TRAF3 as a candidate tumor suppressor gene involved in lymphomagenesis. Here, we studied the TRAF3 gene in 30 chronic lymphocytic leukemias (CLLs) and 11 B-cell lymphomas of different subtypes including marginal zone lymphoma and B-cell lymphoma not otherwise specified. All cases carried a 14q-deletion with the typical break points in the ZFP36L1 region in 14q24.1 and the IGH locus in 14q32.33 as shown by fluorescence in situ hybridization (FISH). By FISH we screened the 41 cases for homozygous deletions in the TRAF3 region using a dual-color FISH assay (BAC clone CTD-3235K2 for the TRAF3 locus and BAC clone RP11-977G1 as internal control, Supplementary Information). We identified two cases (case 1 and 2) harboring homozygous deletions of the TRAF3 locus in 62 and 76% of the cells, respectively. In addition, case 1 showed a signal pattern indicating a heterozygous deletion of the TRAF3 region in 14% of the nuclei suggesting that the homozygous deletion was a secondary event (Figure 1a) . High resolution array CGH (Agilent, 244 K and NimbleGen, 385 K) confirmed the homozygous deletions and sized them to approximately 690 kb (chr14:101 988 kb-102 675 kb) and 670 kb (chr14:102 000 kb-102 669 kb) (Figure 1b) (Supplementary Information). Remarkably, the centromeric and the telomeric break points of both homozygous deletions cluster within 6 and 12 kb in the regions of the genes KIAA0329 and TNFAIP2, respectively. Furthermore, FISH identified four cases (cases 3-6) with homozygous deletions of TRAF3 in subclones with 7-14% of the nuclei (cutoff for homozygous loss: o1%).
To investigate whether the remaining TRAF3 allele in the cases with heterozygous TRAF3 deletion could be inactivated by mutations, the 10 coding exons of TRAF3 (exon 3-12; NM_145725) were screened by denaturing high performance liquid chromatography. PCR products with aberrant denaturing high performance liquid chromatography chromatogram were subjected to sequence analysis (Supplementary Information, Supplementary Table 2) . From 31 del(14)(q24.1q32.33)-positive cases with available DNA and a tumor cell content of X35%, three cases showed a total of five mutations presumably disturbing the TRAF3 function (Supplementary Figure 1) . These comprise two frameshift mutations leading to truncated proteins, two splice site mutations and one missense mutation affecting the consensus sequence of the ring finger motif (Figure 1c) . 7 There is no evidence for polymorphisms at these DNA sequence positions in the Human Genome Browser database (http:// genome.ucsc.edu/) and denaturing high performance liquid chromatography or sequencing analyses failed to detect these five alterations in at least 50 DNA samples derived from peripheral blood of healthy individuals. The cases with biallelic TRAF3 aberrations are summarized in Table 1 .
TRAF3 mRNA expression determined by quantitative reverse transcription PCR in nine del(14)(q24.1q32.33)-positive cases without homozygous TRAF3 deletion was compared with that in 11 B-CLLs without TRAF3-aberration by FISH (Supplementary Information). All cases had a tumor cell content of more than 40%. Cases with TRAF3 deletion showed significantly lower expression of TRAF3 mRNA compared with B-CLLs without TRAF3 deletion (P ¼ 0.0008) (Figure 1d ).
To investigate whether low expression of TRAF3 in cases with heterozygous 14q-deletion might be because of aberrant promoter methylation, we performed methylation-specific PCR in 32 cases with del(14)(q24.1q32.33) (Supplementary Information). Though no CpG-island has been assigned to TRAF3, it contains a highly conserved, CpG-rich region within the promoter region (http://genome.ucsc.edu/cgi-bin/hgGateway). We established two methylation-specific PCR assays, one targets a region located 58 bp upstream of the transcription start site in the first non-coding exon of TRAF3, whereas the other one 14q-alterations are indicated in bold letters.
Letters to the Editor 2154 targets a conserved E2F transcription factor-binding site 546 bp upstream of the transcription start site (Supplementary Table 3 ). All 32 cases analyzed showed the pattern for unmethylated DNA like the controls (data not shown).
In this study, we identified biallelic inactivation of TRAF3 (9/41, 22%) and lower expression of TRAF3 mRNA in B-cell neoplasias with deletion del(14)(q24.1q32.33) due to breaks in IGH and ZFP36L1 regions. Abnormalities that inactivate the TRAF3 protein lead to constitutive NF-kB activation, 4, 6 which is a known mechanism in various cancer types to block apoptosis. 8 The ring finger domain and the TRAF3 domain are the critical components of TRAF3 for the suppression of NIK protein levels and the subsequent inhibition of NF-kB2. 7 At least one of the two domains is affected in each of the three TRAF3-mutated alleles, suggesting TRAF3 inactivation in these cases. The fact that we observed cases with subclonal homozygous deletion of the second TRAF3 allele indicates that this loss occurred secondary during tumor progression. It is still possible that oncogene activation through juxtaposition of IGH in 14q32.33 to the chromosomal region in 14q24.1 is the major mechanism in lymphomagenesis conferred by the deletion del(14)(q24.1q32.33). Complete loss of functional TRAF3 by inactivation of the remaining allele may induce a further selective advantage of the tumor cells. B-cell-specific TRAF3 À/À mice show an increased production of immunoglobulins. 7 Therefore, it is intriguing to speculate that loss of functional TRAF3 in cases with deletion del(14)(q24.1q32.33) leads to stronger activation of the immunoglobulin enhancer and, subsequently, a stronger activation of a putative oncogene in 14q24 that is juxtaposed to the IGH locus.
